

1 **Non-retroviral endogenous viral element limits cognate virus replication**
2 **in *Aedes aegypti* ovaries**

3
4 Yasutsugu Suzuki^{1*}, Artem Baidaliuk^{2,3*}, Pascal Miesen^{1,4}, Lionel Frangeul¹, Anna B. Crist²,
5 Sarah H. Merklings², Albin Fontaine^{2†}, Sebastian Lequime⁵, Isabelle Moltini-Conclois², Hervé
6 Blanc¹, Ronald P. van Rij⁴, Louis Lambrechts^{2**§}, Maria-Carla Saleh^{1**§}.

7
8 ¹Viruses and RNA Interference Unit, Institut Pasteur, UMR3569, CNRS, Paris, France.

9 ²Insect-Virus Interactions Unit, Institut Pasteur, UMR2000, CNRS, Paris, France

10 ³Sorbonne Université, Collège doctoral, F-75005 Paris, France

11 ⁴Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud
12 University Medical Center, Nijmegen, The Netherlands

13 ⁵KU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of
14 Clinical and Epidemiological Virology, Leuven, Belgium

15
16 *These authors contributed equally

17 †Current address: Unité de Parasitologie et Entomologie, Institut de Recherche Biomédicale
18 des Armées (IRBA), Marseille, France; IRD, AP-HM, SSA, UMR Vecteurs – Infections
19 Tropicales et Méditerranéennes (VITROME), IHU - Méditerranée Infection, Aix Marseille
20 Université, Marseille, France

21 **These authors contributed equally

22 §Corresponding authors: louis.lambrechts@pasteur.fr; carla.saleh@pasteur.fr

23 Address: 28 rue du Docteur Roux 75015 Paris, France

24
25 **Running title:** EVE controls CFAV replication in mosquito ovaries

28 **Summary**

29 Endogenous viral elements (EVEs) are viral sequences integrated in host genomes. A
30 large number of non-retroviral EVEs was recently detected in *Aedes* mosquito
31 genomes, leading to the hypothesis that mosquito EVEs may control exogenous
32 infections by closely related viruses. Here, we experimentally investigated the role of
33 an EVE naturally found in *Aedes aegypti* populations and derived from the widespread
34 insect-specific virus, cell-fusing agent virus (CFAV). Using CRISPR/Cas9 genome
35 editing, we created an *Ae. aegypti* line lacking the CFAV EVE. Absence of the EVE
36 resulted in increased CFAV replication in ovaries, possibly modulating vertical
37 transmission of the virus. Viral replication was controlled by targeting of viral RNA by
38 EVE-derived piRNAs. Our results provide evidence that antiviral piRNAs are produced
39 in the presence of a naturally occurring EVE and its cognate virus, demonstrating a
40 functional link between non-retroviral EVEs and antiviral immunity in a natural insect-
41 virus interaction.

42 **Introduction**

43 Host genomes often harbor fragments of viral genomes, referred to as endogenous
44 viral elements (EVEs), that are inherited as host alleles (Holmes, 2011). The best-
45 studied EVEs are derived from mammalian retroviruses, which actively integrate their
46 viral DNA into the host genome during their replication cycle. Retroviral EVEs play
47 important roles in host physiology and antiviral immunity (Frank and Feschotte, 2017).
48 Recent bioinformatic surveys also identified non-retroviral EVEs in a wide range of
49 animal genomes, albeit their function was only studied in cell lines or protozoa (Belyi
50 et al., 2010; Flynn and Moreau, 2019; Fujino et al., 2014; Horie et al., 2010; Katzourakis
51 et al., 2014; Palatini et al., 2017; Parry and Asgari, 2019; Ter Horst et al., 2019;
52 Waldron et al., 2018). The endogenization of non-retroviral sequences is presumably
53 mediated by the activity of transposable elements (TEs), which are mobile DNA
54 sequences ubiquitously found in eukaryotic genomes. Non-retroviral EVEs are often
55 integrated in genomic regions surrounded by TEs, suggesting that TEs are involved in
56 the integration and/or expansion of the EVEs (Gilbert and Feschotte, 2010; Horie et
57 al., 2010; Palatini et al., 2017; Suzuki et al., 2017; Whitfield et al., 2017). The reverse
58 transcription activity of retrotransposons is the likely mechanism generating non-
59 retroviral DNA from RNA viruses, which are the hypothetical precursors of non-
60 retroviral EVEs (Goic et al., 2016).

61

62 The recent discovery of non-retroviral EVEs in the genomes of mosquito vectors
63 (Lequime et al., 2017; Palatini et al., 2017; Whitfield et al., 2017) has stimulated studies
64 to elucidate their potential function. In particular, the genomes of the main arthropod-
65 borne virus (arbovirus) vectors *Aedes aegypti* and *Aedes albopictus* harbor hundreds
66 of non-retroviral EVEs predominantly derived from insect-specific viruses of the

67 *Flaviviridae* and *Rhabdoviridae* families (Palatini et al., 2017; Whitfield et al., 2017).
68 Interest in mosquito EVEs stems from the hypothesis that they may serve as the source
69 of immunological memory against exogenous viruses in insects, as was recently
70 reviewed in (Blair et al., 2020). This hypothesis largely relies on the observation that
71 EVEs and their flanking genomic regions serve as templates for P-element-induced
72 wimpy testis (PIWI)-interacting RNAs (piRNAs) (Palatini et al., 2017; Suzuki et al.,
73 2017; Ter Horst et al., 2019; Whitfield et al., 2017). piRNAs are a major class of small
74 RNAs (sRNAs) and are typically generated from genomic loci called piRNA clusters
75 (Ozata et al., 2019). The piRNA pathway is considered a widely conserved TE-
76 silencing system to prevent deleterious effects of transposition events in eukaryotic
77 genomes, particularly in gonads (Cosby et al., 2019). In fact, production of EVE-
78 derived piRNAs is observed across a wide range of animals such as mammals,
79 arthropods and sea snails (Palatini et al., 2017; Parrish et al., 2015; Sun et al., 2017;
80 Suzuki et al., 2017; Ter Horst et al., 2019; Waldron et al., 2018; Whitfield et al., 2017),
81 in which EVEs are often enriched in piRNA clusters (Parrish et al., 2015; Russo et al.,
82 2019; Ter Horst et al., 2019). The predominantly anti-sense orientation of EVE-derived
83 piRNAs supports the idea that piRNAs could also mediate antiviral immunity by
84 targeting exogenous viral RNA with high levels of sequence identity (Palatini et al.,
85 2017; Russo et al., 2019; Whitfield et al., 2017).

86

87 The biogenesis of piRNAs and their function as a TE-silencing mechanism to protect
88 genome integrity are well described in the model insect *Drosophila* (Czech and
89 Hannon, 2016). piRNAs are characterized by their size of 26-30 nucleotides (nt) and
90 distinctive sequence biases. Primary piRNAs typically display a uridine at the first
91 nucleotide position, referred to as 1U bias. Secondary piRNAs overlap primary piRNAs

92 over 10 nt at their 5' extremity and display an adenine at their 10th nt position, referred
93 to as 10A bias (Brennecke et al., 2007; Gunawardane et al., 2007). These
94 characteristics are a consequence of piRNA reciprocal amplification during the ping-
95 pong cycle: (i) primary piRNAs are generated from single-stranded precursor RNA, (ii)
96 primary piRNAs guide the cleavage of complementary RNA sequences, (iii) secondary
97 piRNAs are generated from the 3' cleavage products, (iv) secondary piRNAs induce
98 cleavage of piRNA precursor transcripts, which are processed into primary piRNAs.
99 Unlike *Drosophila*, it has been shown that mosquitoes produce virus-derived primary
100 and secondary piRNAs during viral infections (Morazzani et al., 2012; Petit et al., 2016;
101 Vodovar et al., 2012). Although most of these observations have been obtained using
102 the *Ae. aegypti* cell line Aag2 and arboviruses such as dengue or Sindbis viruses,
103 recent studies have shown that viral piRNAs were also found in mosquito cell lines
104 persistently infected with insect-specific viruses, which are not infectious to vertebrates
105 (Goertz et al., 2019; Rückert et al., 2019).

106

107 Whether EVEs can protect insects, and most importantly their germline, from viral
108 infection through the piRNA pathway, has not been demonstrated *in vivo*. In
109 mosquitoes, the antiviral activity of viral piRNAs is still debated and a direct link
110 between EVEs and antiviral activity has yet to be established (Blair, 2019). One
111 observation casting doubt on this hypothesis is that most arthropod EVEs identified so
112 far are unlikely to serve as sources of antiviral piRNAs because they are not similar
113 enough to currently circulating viruses (Parrish et al., 2015; Russo et al., 2019; Ter
114 Horst et al., 2019). Here, we identified a new EVE in *Ae. aegypti* sharing ~96%
115 nucleotide identity with a wild-type strain of cell-fusing agent virus (CFAV) that we
116 previously isolated from *Ae. aegypti* in Thailand (Baidaliuk et al., 2019). CFAV is a

117 widespread insect-specific virus infecting *Ae. aegypti* populations around the world
118 (Baidaliuk et al., in press). We used this naturally occurring CFAV EVE and the cognate
119 CFAV strain to experimentally investigate the antiviral function of mosquito EVEs in a
120 natural insect-virus interaction. Analysis of sRNAs showed that the CFAV EVE
121 produced primary piRNAs in the absence of CFAV infection. When mosquitoes were
122 infected with CFAV, abundant CFAV-derived piRNAs were produced from the viral
123 genomic regions overlapping with the CFAV EVE. piRNAs displayed a ping-pong
124 signature as well as nucleotide biases consistent with production of EVE-derived
125 primary piRNAs and virus-derived secondary piRNAs. Excision of the CFAV EVE by
126 CRISPR/Cas9 genome engineering resulted in increased CFAV replication in ovaries.
127 Our results provide empirical evidence that a non-retroviral EVE in *Ae. aegypti*
128 contributes to the control of *in vivo* replication of a closely related exogenous virus via
129 the piRNA pathway.
130

131 **Results**

132 ***Survey of CFAV-derived EVEs in Aedes aegypti genome sequences***

133 In order to inventory CFAV-derived EVEs, we used BLAST search to identify CFAV-
134 like sequences in publicly available *Ae. aegypti* genome assemblies, RNA sequencing
135 data and whole-genome sequencing data. We identified several potential EVE
136 structures based on samples for which reads aligned only to segments of the CFAV
137 genome, in addition to samples for which reads covered the entire CFAV genome,
138 presumably representing true CFAV infections (Figure S1). The predicted structure of
139 two of these putative EVEs, which we designated CFAV-EVE1 and CFAV-EVE2, was
140 obtained by *de novo* assembly (Figure 1A). These two putative EVEs were confirmed
141 in an outbred *Ae. aegypti* colony derived from a wild population in Thailand and
142 maintained in our laboratory since 2013. Using specific primer sets (Table S1), we
143 detected CFAV-EVE1 and CFAV-EVE2 in 7 out of 8 and in 3 out of 8 individuals,
144 respectively, in this outbred mosquito colony (Figure 1B).

145

146 ***CFAV-EVEs produce piRNAs that interact with viral RNA from a natural CFAV*** 147 ***infection***

148 Our outbred *Ae. aegypti* colony from Thailand is naturally infected with a wild-type
149 strain of CFAV, which we previously isolated and named CFAV-KPP (Baidaliuk et al.,
150 2019). Only a fraction of the mosquitoes in this colony are naturally infected, allowing
151 us to investigate whether the CFAV EVEs produce piRNAs in the presence or absence
152 of a natural CFAV infection. We sequenced sRNA libraries from both naturally infected
153 and uninfected mosquito pools to examine sRNA production and specifically, EVE-
154 derived and virus-derived piRNA production. In uninfected mosquitoes, the size
155 distribution of the sRNA reads mapping to the CFAV-KPP genome sequence (Figure

156 1C) showed production of sRNAs of 26-30 nt in size with 1U bias, indicating that they
157 are primary piRNAs generated mainly from the CFAV-EVE1 NS2 fragment, and to a
158 lesser extent from the CFAV-EVE2 (Figure 1E). The lack of virus-derived 21-nt small
159 interfering RNAs (siRNAs) confirmed the lack of CFAV infection in these mosquitoes
160 (Figure 1C and Figure S2A). In contrast, the sRNA size profile of mosquitoes naturally
161 infected with CFAV-KPP showed abundant production of virus-derived siRNAs (Figure
162 1D and Figure S2B). The CFAV-infected mosquitoes also harbored positive-stranded
163 (+) CFAV-derived piRNAs, in addition to more abundant negative-stranded (-) primary
164 piRNAs derived from both EVEs (Figure 1F) relative to the uninfected mosquitoes
165 (Figure 1E). The presence of the 10A bias in (+) piRNAs and the 10-nt overlap
166 probability between piRNA reads mapping to opposite strands was consistent with
167 production of secondary virus-derived (+) piRNAs potentially triggered by EVE-derived
168 (-) piRNAs, likely resulting in ping-pong amplification (Figure 1F). Thus, sRNA profiles
169 in our outbred *Ae. aegypti* colony showed that the RNA transcribed from CFAV EVEs
170 interacts with the viral RNA of a natural CFAV infection via the piRNA pathway.

171

172 ***piRNAs from CFAV-EVE1 interact with viral RNA during CFAV experimental*** 173 ***infection***

174 To experimentally demonstrate the role of EVEs in antiviral immunity, we took
175 advantage of a CFAV-free isofemale line of *Ae. aegypti* from Thailand maintained in
176 our laboratory since 2010 (Fansiri et al., 2013; Lequime et al., 2016). We sequenced
177 the whole genome of this isofemale line and only detected the presence of CFAV-
178 EVE1 in the absence of other CFAV EVEs. CFAV-EVE1 was fully reconstructed from
179 the newly obtained genomic data (Figure 2A, Table S2). The structure of CFAV-EVE1
180 in the isofemale line was consistent with the structure predicted from our bioinformatic

181 survey (Figure 1A). CFAV-EVE1 consists of four adjacent fragments that correspond
182 to the following CFAV genomic regions: NS5, NS4B-NS5, NS4A, and NS2A-
183 NS2B/FIFO (designated as NS2 hereafter for simplicity). The CFAV-EVE1 sequence
184 contains multiple start and stop codons in all six open reading frames. Moreover, two
185 fragments (NS2 and NS4A) are inserted in opposite direction relative to the other EVE
186 fragments, making it unlikely that functional viral peptides are effectively translated.
187 We tested 31 individual mosquitoes from the isofemale line and found that 28 (90%;
188 95% confidence interval 73%-97%) were positive for CFAV-EVE1. As previously
189 reported for other EVEs (Palatini et al., 2017; Suzuki et al., 2017; Ter Horst et al., 2019;
190 Whitfield et al., 2017), CFAV-EVE1 and its flanking regions produced abundant
191 antisense piRNAs (Figure 2B) when aligned to the isofemale line genome sequence.
192 This observation indicates that CFAV-EVE1 is likely transcribed as a part of a longer
193 piRNA precursor.

194

195 The CFAV-EVE1 sequence of the isofemale line shared ~96% nucleotide identity with
196 the CFAV-KPP genome, ranging from 94.6% to 98.8% among the different CFAV-
197 EVE1 fragments (Table S2). To experimentally confirm our observations from naturally
198 infected mosquitoes (Figure 1), we investigated the interaction between CFAV-EVE1
199 and the CFAV-KPP strain in the isofemale line (Figure 2C-D). In the absence of CFAV
200 infection and as a consequence of the dual orientation of the CFAV-EVE1 fragments,
201 EVE-derived piRNAs from the NS2 and NS4A regions were in antisense orientation,
202 whereas EVE-derived piRNAs from the NS4B and NS5 regions were in sense
203 orientation relative to the genome sequence of CFAV. We observed the most
204 pronounced production of 1U biased, antisense primary piRNAs in the NS2 region
205 (black frame in top panel of Figure 2E). When mosquitoes were inoculated with CFAV-

206 KPP, the sRNA size profile (Figure 2D) showed abundant production of virus-derived
207 siRNAs (21 nt) and also (+) CFAV-derived piRNAs corresponding to the CFAV-EVE1
208 genomic region of CFAV, in addition to (-) primary piRNAs derived from the EVE. As
209 the NS2 region is the most abundantly covered by both sense and antisense piRNAs,
210 we used this region (black frame in top panel of Figure 2F) to check for 10A bias as
211 well as ping-pong signature. The 10-nt overlap of 5' ends was consistent with active
212 ping-pong amplification of the piRNAs in the NS2 region. In addition, analysis of the
213 reads that unambiguously mapped to either the CFAV-KPP genome or to the CFAV-
214 EVE1 sequence revealed that the vast majority of the piRNA reads derived from the
215 CFAV-KPP genome were (+) piRNAs (Figure S3A) whereas almost all of the (-) piRNA
216 reads derived from the CFAV-EVE1 (Figure S3B). It is worth noting that despite a
217 similar abundance of EVE-derived primary piRNAs from the NS2 and NS4B regions in
218 the absence of infection (Figure 2E), there is no evidence for amplification of piRNAs
219 from the NS4B region during infection (Figure 2F). This suggests that the CFAV (-)
220 RNA is not accessible or abundant enough for PIWI proteins loaded with primary
221 piRNAs to initiate the ping-pong cycle.

222

223 Altogether, these results confirmed that CFAV-EVE1 produces piRNAs that target viral
224 RNA and engage in a ping-pong cycle during experimental CFAV infection. The ability
225 to experimentally infect the mosquito isofemale line carrying only CFAV-EVE1 with the
226 CFAV-KPP strain allowed us to directly address the role of non-retroviral EVEs in
227 antiviral immunity. This system recapitulated, under laboratory conditions, a unique
228 situation found in nature (i.e., mosquitoes carrying an EVE that are infected or
229 uninfected with a cognate virus).

230

231 ***Genome engineering of a CFAV-EVE1 knockout line of Aedes aegypti***

232 To directly test if the presence of CFAV-EVE1 influences CFAV replication in *Ae.*
233 *aegypti*, we used CRISPR/Cas9 genome editing to create a CFAV-EVE1 knockout (-/-
234) line and a homozygous CFAV-EVE1 control (+/+) line derived from our CFAV-free
235 isofemale line. We designed two single-guide RNAs (sgRNAs) targeting the
236 boundaries of CFAV-EVE1 and another sgRNA in the middle of CFAV-EVE1 to
237 promote excision (Figure 3A, Table S3). The sgRNAs were injected together with
238 recombinant Cas9 into mosquito embryos. We obtained a heterozygous male devoid
239 of CFAV-EVE1 (Figure 3B) that was outcrossed with wild-type mosquitoes from the
240 parental isofemale line for two consecutive generations. The progeny were carefully
241 sorted into purely CFAV-EVE1 homozygous (+/+) and knockout (-/-) mosquitoes.
242 Importantly, the CFAV-EVE1 (-/-) mosquitoes only included the genetically engineered
243 deletion genotype and excluded individuals that could be naturally devoid of CFAV-
244 EVE1.

245

246 ***CFAV-derived piRNA production is strongly reduced in the absence of CFAV-
247 EVE1***

248 To determine if the absence of CFAV-EVE1 affected the production of CFAV-derived
249 piRNAs, we infected CFAV-EVE1 (+/+) and CFAV-EVE1 (-/-) mosquitoes with CFAV-
250 KPP. Seven days post infection, we dissected ovaries (germline tissue) and heads
251 (somatic tissue) to prepare sRNA libraries from both tissues. Ovaries of mock-infected
252 mosquitoes from the CFAV-EVE1 (+/+) line displayed the same sRNA profile (Figure
253 S4A) as whole mosquitoes from the parental isofemale line (Figure 2C), with (-)
254 piRNAs mainly derived from the NS2 region of CFAV-EVE1 and a 1U bias (Figure 2E
255 and S4C). The heads of mock-infected mosquitoes (Figure S4E) contained few

256 piRNAs mapping to the CFAV genome (<30 reads), consistent with the notion that
257 germline tissues are the main producers of piRNAs (Akbari et al., 2013). As expected,
258 mock-infected individuals from the CFAV-EVE1 (-/-) line did not harbor any piRNAs
259 mapping to the CFAV genome in their ovaries and heads (Figure S4B, D, F, H). This
260 result confirmed that genome editing effectively removed the CFAV-EVE1 sequence
261 and allowed us to test whether the absence of the EVE affected the production of virus-
262 derived piRNAs upon experimental CFAV-KPP infection. Of note, we detected a small
263 number of viral siRNAs mapping to the CFAV genome in mock-infected heads of the
264 CFAV-EVE1 (+/+) line (86 reads) and the CFAV-EVE1 (-/-) line (15 reads). As these
265 samples were run in the same flow cell that contained CFAV-infected samples (Figure
266 4) producing thousands of viral siRNA reads in head tissues (31,988 reads in the
267 CFAV-EVE1 (+/+) line and 8,465 reads in the CFAV-EVE1 (-/-) line), the minute
268 amount of viral siRNA detected in mock conditions is likely due to demultiplexing cross
269 contamination, a common and recurrent problem in high-throughput sequencing of
270 multiplexed samples (Ballenghien et al., 2017).

271
272 Following CFAV-KPP inoculation, we detected abundant viral siRNAs in both CFAV-
273 EVE1 (+/+) and CFAV-EVE1 (-/-) mosquitoes (Figure 4A and Figure 4B). In addition,
274 we detected virus-derived piRNAs and EVE-derived piRNAs with 1U and 10A bias and
275 ping-pong amplification signature in the ovaries of CFAV-EVE1 (+/+) mosquitoes
276 (Figure 4C). In contrast, (+) piRNAs mapping to the NS2 region of the CFAV-KPP
277 genome were barely detectable in the ovaries of CFAV-EVE1 (-/-) mosquitoes (Figure
278 4D). Importantly, the detection of reads that unambiguously mapped to the virus
279 showed that, even in the absence of the EVE, piRNAs were still produced from the
280 virus genome upon infection (Figure S5A).

281

282 CFAV-KPP infection in the heads of CFAV-EVE1 (+/+) mosquitoes resulted in the
283 production of CFAV-derived siRNAs as well as piRNAs (Figure 4E). The piRNAs
284 corresponding to the NS2 region were in both sense and antisense orientation,
285 presented a 1U-10A bias and 10-nt overlap of 5' ends (Figure 4G). CFAV-KPP
286 infection in the heads of CFAV-EVE1 (-/-) mosquitoes resulted in abundant CFAV-
287 derived siRNAs (Figure 4F) and only piRNAs in sense orientation, without a ping-pong
288 amplification signature, corresponding to primary piRNA production from the virus
289 genome (Figure 4H and Figure S5B).

290

291 Altogether, these results showed that the production of CFAV-derived piRNAs is
292 profoundly modified in the absence of CFAV-EVE1. Production of primary piRNAs from
293 CFAV-EVE1 is necessary to trigger the production of secondary virus-derived piRNAs
294 from the virus genome. This observation suggests that piRNAs could have an antiviral
295 activity in the joint presence of an EVE and its cognate virus.

296

297 ***Increased CFAV replication in ovaries in the absence of CFAV-EVE1***

298 To assess the antiviral effect of piRNAs derived from the interaction between the EVE
299 and the virus, we compared CFAV replication in CFAV-EVE1 (-/-) and CFAV-EVE1
300 (+/+) mosquitoes. To do so, we measured viral RNA levels in the heads and ovaries of
301 females 4 and 7 days after CFAV inoculation. We performed six separate experiments
302 using the same infectious dose and readout. The total amount of CFAV RNA produced
303 by infected ovaries was significantly lower than the viral RNA produced in the heads
304 (Figure 5). There was no consistent difference between mosquito lines across
305 experiments for the CFAV RNA loads in heads collected on day 4 post inoculation

306 (Figure 5A, Table S4). Accounting for the inter-experiment variation, there was a
307 significant difference of CFAV RNA loads in ovaries on day 4 post inoculation, with
308 CFAV replicating to higher levels in absence of the CFAV-EVE1 (Figure 5A, Table S4).
309 On day 7 post inoculation, CFAV RNA loads were significantly higher in mosquito
310 heads (Figure 5B, Table S4) and even more so in mosquito ovaries (Figure 5B, Table
311 S4) in the absence of the CFAV-EVE1. Together, these experiments showed that
312 CFAV replicated to higher levels in the absence of CFAV-EVE1, most prominently in
313 ovaries. These results demonstrate the antiviral activity of an EVE against its cognate
314 virus.

315 **Discussion**

316

317 The notion that non-retroviral EVEs could play a role in eukaryotic host immunity
318 similar to retroviral EVEs (Anderson et al., 2000; Best et al., 1996) has recently gained
319 traction. Several studies attempted to prove that non-retroviral EVEs contribute to the
320 immune antiviral response. Perhaps the best example is Borna disease virus (BDV)
321 and its endogenous bornavirus-like element, which affects BDV polymerase activity
322 and inhibits virus replication in a mammalian cell line when incorporated into the viral
323 ribonucleoprotein (Fujino et al., 2014). Tassetto *et al.* observed that mosquito cells
324 carrying an EVE related to CFAV were partially protected against a recombinant
325 Sindbis virus engineered to contain the EVE sequence (Tassetto et al., 2019). These
326 *in vitro* experiments suggested that non-retroviral EVEs integrated in the host genome
327 may provide antiviral protection against exogenous cognate viruses, but direct
328 evidence from a natural system *in vivo* had not been provided until now.

329

330 The hypothesis that non-retroviral EVEs participate in antiviral immunity stems largely
331 from accumulating evidence that they produce primary piRNAs (Palatini et al., 2017;
332 Parrish et al., 2015; Sun et al., 2017; Suzuki et al., 2017; Ter Horst et al., 2019;
333 Waldron et al., 2018; Whitfield et al., 2017). The piRNA pathway is often referred to as
334 the guardian of genome integrity because its canonical function is to silence TEs in the
335 germline (Czech et al., 2018). piRNA precursors are transcribed from genomic loci
336 harboring transposon fragments that provide a genetic memory of past transposition
337 invasion. The widespread occurrence of non-retroviral EVEs in *Aedes* mosquito
338 genomes (Palatini et al., 2017; Whitfield et al., 2017) could reflect a similar mechanism
339 whereby the function of EVEs would be to silence exogenous viruses with

340 complementary sequences (Blair et al., 2020). A major challenge to prove this
341 hypothesis is that the viruses currently circulating generally do not share a high
342 nucleotide identity with the corresponding EVE sequences, preventing a possible
343 match between EVE-derived piRNAs and the target viral RNA. In the present study,
344 we overcame this obstacle by identifying a new EVE in *Ae. aegypti* mosquitoes from
345 Thailand that is highly similar (~96% nucleotide identity) to a contemporaneous CFAV
346 strain. We used this naturally occurring insect-virus interaction to test the hypothesis
347 that a non-retroviral EVE can inhibit virus replication via the piRNA pathway *in vivo*.

348

349 Our results revealed that during both natural infection (mosquitoes carrying the CFAV
350 EVE and naturally infected with CFAV) and controlled infection (mosquitoes carrying
351 the CFAV EVE and experimentally inoculated with CFAV), the RNAs from the EVE
352 and the virus interact through the piRNA pathway, resulting in inhibition of virus
353 replication (Figure 6). Evidence of this interaction is provided by the abundant
354 secondary piRNAs produced via the ping-pong amplification mechanism. Only when
355 viral RNA is in presence of EVE-derived primary piRNAs does the piRNA pathway
356 acquire its antiviral activity. Viral piRNAs alone are insufficient to induce this effect.
357 Although viral piRNAs are commonly detected in mosquitoes (Miesen et al., 2016),
358 their antiviral function has remained equivocal (Blair et al., 2020). Our study provides
359 a clear demonstration that the piRNA pathway is involved in the mosquito antiviral
360 response.

361

362 We observed that the piRNA-mediated antiviral effect of the CFAV EVE was strongest
363 in the ovaries. Although recent research on arthropods suggests that protecting the
364 germline was not necessarily its ancestral role (Lewis et al., 2018), our results are

365 consistent with a specialized role of non-retroviral EVE-mediated antiviral immunity in
366 germ cells. Presently, little is known about the pathogenicity of insect-specific viruses
367 in mosquitoes in nature. However, because they are thought to be primarily transmitted
368 vertically from mother to offspring, it is likely that insect-specific viruses reduce
369 fecundity and/or fertility of their host. We speculate that the EVE-piRNA pathway
370 combination may have evolved to control the replication of vertically transmitted
371 viruses in the germline and maintain high fecundity and fertility. In fact, minimizing the
372 detrimental effects of viral infection in the germline benefits both the host and the virus
373 because the fitness of vertically-transmitted viruses is directly linked to their host's
374 reproductive success (Anderson and May, 1982; Ewald, 1983, 1987).

375

376 Another open question is the degree of nucleotide identity required between the EVE
377 and the virus for the antiviral activity to take place. Sequence mismatches reduce
378 piRNA binding to its target sequences and it was shown that more than three
379 mismatches can effectively abolish piRNA recognition of the target sequence in
380 *Drosophila* (Huang et al., 2013). Even single mismatches in the seed sequence
381 strongly reduces piRNA silencing efficiency in *Ae. aegypti* (Halbach et al., 2020).
382 Therefore, viruses could escape EVE-mediated immunity by acquiring mutations,
383 resulting in a possible coevolutionary arms race. Predicting the tempo and mode of
384 such coevolutionary dynamics is difficult even when the fitness cost of individual
385 mutations is known (Chabas et al., 2019). Interestingly, in our study the NS2 region of
386 the CFAV EVE was most tightly involved in the interaction with the virus. This region
387 corresponds to *fifo*, an open-reading frame (ORF) resulting from a ribosomal frameshift
388 exclusively found in insect-specific flaviviruses (Firth et al., 2010). The existence of two
389 overlapping ORFs in this region (main frame and -1 frame) thus constrains sequence

390 evolution. We speculate that this region may have been specifically retained as an
391 EVE in the *Ae. aegypti* genome because the high level of purifying selection in the *fifo*
392 region may prevent CFAV from escaping the antiviral mechanism by sequence
393 divergence.

394

395 In view of our results and the increasing body of evidence from the literature (Ophinni
396 et al., 2019), we conclude that EVEs constitute a universal system of heritable,
397 sequence-specific antiviral immunity in eukaryotes, analogous to CRISPR/Cas
398 immunity in prokaryotes. In the particular case of mosquitoes, integration of non-
399 retroviral sequences into the host genome, their transcription within piRNA clusters,
400 and their processing into antiviral sRNAs constitutes a mechanism by which these
401 acquired viral sequences are coopted to serve host immunity.

402

403 **Acknowledgements**

404 We thank Catherine Lallemand for assistance with mosquito rearing. We are grateful
405 to Catherine Bourgouin and Nicolas Puchot for assistance with the microinjection
406 apparatus and to Anavaj Sakuntabhai for facilitation of the mosquito genome
407 sequencing. R.v.R. was supported by the Netherlands Organization for Scientific
408 Research (VICI grant 016.VICI.170.090). P.M. was supported by a short-term
409 fellowship of the European Molecular Biology Organization (EMBO grant ASTF 449-
410 2016). Work in the laboratory of L.L. was supported by Agence Nationale de la
411 Recherche (grants ANR-16-CE35-0004-01 and ANR-17-ERC2-0016-01) and the City
412 of Paris Emergence(s) program in Biomedical Research. Work in the laboratory of
413 M.C.S. was supported by the European Research Council (FP7/2013-2019 ERC CoG
414 615220). L.L. and M.C.S were financed by the French Government's Investissement

415 d’Avenir program Laboratoire d’Excellence Integrative Biology of Emerging Infectious
416 Diseases (grant ANR-10-LABX-62-IBEID). The funders had no role in study design,
417 data collection and interpretation, or the decision to submit the work for publication.

418

419 **Author Contributions**

420 A.B., Y.S., P.M., L.L., and M.C.S conceptualized the study. A.B. and Y.S. coordinated
421 and performed infection experiments, analyzed and visualized the data, wrote the first
422 draft and edited the manuscript. I.M.-C. participated in the infection experiments. H.B.
423 performed sRNA sequencing. L.F. and P.M. analyzed and visualized sRNA
424 sequencing data. A.B.C. generated genetically modified *Ae. aegypti* lines. S.H.M
425 participated in the generation of the genetically modified mosquito lines. A.B.
426 participated in the rearing of the genetically modified mosquito lines. A.F. conducted
427 whole-genome sequencing and L.F. analyzed the whole-genome sequencing data.
428 S.L. participated in the screening of the SRA database for CFAV-like sequences.
429 R.v.R. participated in the interpretation of the results. L.L. and M.C.S supervised the
430 study, provided resources, and edited the manuscript.

431

432 **Declaration of Interests**

433 The authors declare that there is no conflict of interest.

434 **Methods**

435 **Ethics statement**

436 Genetic modification of *Ae. aegypti* was performed under authorization number 4018
437 (bis) from the French Ministry of Higher Education, Research and Innovation.

438

439 **Survey of CFAV-related EVEs in public sequencing data of *Aedes aegypti***

440 The accession numbers for the *Ae. aegypti* sequencing data were selected using the
441 web platform of the SRA database (Leinonen et al., 2011). We used BLAST
442 (megablast) search (Altschul et al., 1990) implemented in the SRA Toolkit (Leinonen
443 et al., 2011) to search for CFAV-like sequences in the preselected SRA data. The
444 BLAST search resulted in 597 RNA-seq and 552 WGS runs tested, released before
445 January 30 and February 6, 2020, respectively. Full-genome CFAV sequences from
446 Thailand CFAV-Bangkok (European Nucleotide Archive, LR694074) (Zakrzewski et
447 al., 2018) and CFAV-KPP (European Nucleotide Archive, LR596014) (Baidaliuk et al.,
448 2019) were used as queries. Visualization of positive hits was performed in R v3.6.1
449 (<http://www.r-project.org/>). Using the online BLAST tool (megablast), the CFAV-EVE1
450 sequence was detected in the supercontig 1.109 of the AaegL3 genome assembly
451 (GenBank accession number GCA_000004015.3) but absent from the AaegL5
452 genome assembly (GenBank accession number GCA_002204515.1). The CFAV-
453 EVE1 sequence was reconstructed from a published WGS dataset (SRR5562867)
454 using metaSPAdes v3.11.0 (Nurk et al., 2017). Reads from the WGS dataset were first
455 quality trimmed with Trimmomatic v0.36 (Bolger et al., 2014) and aligned against the
456 AaegL5 genome assembly with Bowtie2 v2.3.4.3 (--end-to-end --very-fast) (Langmead
457 and Salzberg, 2012) to filter out all non-EVE reads. The CFAV-EVE2 sequence was
458 reconstructed from SRA samples SAMN04480331, SAMN04480332,

459 SAMN04480333. Reads were trimmed with Cutadapt v1.18 (Martin, 2011). Relaxed
460 local Bowtie2 v2.3.4.3 alignment (--local -D 20 -R 3 -L 11 -N 1 --gbar 1 --mp 3) was
461 used in order to preselect CFAV-derived reads, which were then used for *de novo*
462 assembly with Ray v2.3.1-mpi tool (Boisvert et al., 2010). The contigs obtained from
463 all three SRA samples were combined into a single sequence of CFAV-EVE2 using
464 Geneious (v10.2.3) software (<https://www.geneious.com>). The sequence was then
465 verified by Bowtie2 alignment (--local) of the reads, coverage and single nucleotide
466 variant calculation by bedtools v2.25.0 and LoFreq v2.1.3.1, respectively (Quinlan and
467 Hall, 2010; Wilm et al., 2012). Both CFAV-EVE1 and CFAV-EVE2 sequences with
468 annotations are available in Table S2.

469

470 **Live *Aedes aegypti* mosquitoes**

471 *Mosquito origin and maintenance*

472 An outbred laboratory colony of *Ae. aegypti* mosquitoes originally sampled in 2013
473 from a wild population in Thep Na Korn Village, Kamphaeng Phet Province, Thailand
474 (Lequime et al., 2016) was found to be infected with CFAV (Baidaliuk et al., 2019) and
475 was used in this study for CFAV-EVE1 and CFAV-EVE2 detection by gDNA PCR and
476 sRNA sequencing of naturally infected and uninfected mosquitoes. An isofemale line
477 of *Ae. aegypti* originating from Kamphaeng Phet Province, Thailand was used for
478 experimental infections *in vivo*. The isofemale line was created in 2010 as the progeny
479 of a single-pair mating between a wild male from Mae Na Ree village and a wild female
480 from Nhong Ping Kai village (Fansiri et al., 2013; Lequime et al., 2016). The inability to
481 isolate CFAV from mosquito homogenates on C6/36 (*Ae. albopictus*) cells (ATCC
482 CRL-1660) and negative RT-PCR directly on mosquito RNA confirmed that the
483 isofemale line was CFAV-free. Mosquitoes were maintained under standard insectary

484 conditions (27°C, 70% relative humidity and 12h:12h light:dark cycle). Larvae were
485 reared in plastic trays filled with 1.5 L of dechlorinated tap water at a density of 200
486 larvae per tray and provided with 200 mg of TetraMin fish food (Tetra) on days 0 and
487 2 and 400 mg on day 4. After emergence, adult mosquitoes were housed in plastic
488 cages under standard insectary conditions (27°C, 70% relative humidity and 12h:12h
489 light:dark cycle) and provided with 10% sucrose solution *ad libitum*.

490 *Whole-genome sequencing of the isofemale line*

491 The whole genome of the *Ae. aegypti* isofemale line was sequenced at the 20th
492 generation of colonization. The DNA was extracted from a total of 144 virgin females
493 following a published method (Bender et al., 1983). Six pools of 4 mosquitoes were
494 homogenized in 240 µL of the following buffer: 0.1 M NaCl, 0.2 M sucrose, 0.1 M Tris
495 buffer, 0.05 M EDTA, 0.5% SDS, pH adjusted to 9.2 with NaOH. The homogenates
496 were incubated at 65°C for at least 35 min and 34 µL of 8 M KAc were added to the
497 heated homogenates and cooled on ice for 30 min. Supernatants were transferred to
498 new tubes, mixed with an equal volume of 100% ethanol and incubated for 5 min at
499 room temperature (20-25°C). The DNA was pelleted by 15-min centrifugation at
500 21,100g and washed with 75% ethanol. The pellet was resuspended in 100 µL of
501 PCR-grade water. This procedure was repeated 6 times and DNA elutes from all pools
502 were gathered in a single tube and precipitated by adding 1/10 of 3M NaAc and 2.5x
503 of cold 100% ethanol, followed by a washing step with 75% ethanol. The final elution
504 was done in 400 µL of PCR-grade water. The genomic DNA was treated with RNase
505 A/T1 (Thermo Scientific) for 30 min at 37°C and precipitated with NaAc again. The
506 quality of the resulting DNA was assessed by Nanodrop (Thermo Scientific), Qubit HS
507 DNA Assay Kit (Invitrogen), and 1% agarose gel migration. The DNA sequencing was
508 performed commercially by MacroGen Europe (<http://www.macrogen.com>). A TruSeq

509 PCR-free DNA shotgun library (550-bp inserts) was sequenced on an Illumina HiSeq
510 4000 platform (2 x 100 bp). The genome sequence of the isofemale line was deposited
511 to Genbank (SRA sample SRR01437595).

512 *DNA extraction and CFAV-EVE1-specific and CFAV-EVE2-specific PCRs*

513 To verify the presence and prevalence of the CFAV-EVE1 in the *Ae. aegypti* isofemale
514 line and outbred colony, DNA was extracted by two different methods. Genomic DNA
515 was extracted from single legs of individual mosquitoes or whole individual mosquitoes
516 using NucleoSpin DNA Insect Kit (Machery-Nagel) or NucleoSpin Tissue Kit
517 (Macherey-Nagel) following the manufacturers' instructions. Final elution was
518 performed with 20 μ L of the elution buffer. The DNA was used as a template for CFAV-
519 EVE1-specific qualitative PCR with DreamTaq Green DNA Polymerase (Thermo
520 Scientific) following the manufacturer's recommendations, and using S7, EVE-GT-
521 external, EVE-GTlong-external and/or EVE-GT-internal primers (Table S1). The
522 CFAV-EVE2 sequence was detected with the CFAV-EVE2 primer set (Table S1).

523 Alternatively, DNAzol DIRECT (Molecular Research Center, Inc.) was used following
524 manufacturer's instructions, where DNA was extracted from single legs by placing a
525 leg in 200 μ L of DNAzol DIRECT in a 1.5-mL screw-cap tube partially filled with glass
526 beads and homogenized. The lysate was centrifuged 15-30 sec at 21,100g and
527 incubated at room temperature (20-25°C) for at least 20 min. Subsequently, 0.5-1 μ L
528 of lysate was used directly into a 20- μ L PCR reaction. The same DNAzol DIRECT
529 extraction procedure was used for whole mosquitoes, but the lysate was diluted 1:50
530 in PCR-grade water and 0.5-1 μ L of the dilution was used in a 20- μ L PCR reaction as
531 described above.

532

533 **CRISPR/Cas9-mediated genome engineering**

534 *SgRNA design and synthesis*

535 The *Ae. aegypti* isofemale line containing the CFAV-EVE1 was used to produce pure
536 homozygous CFAV-EVE1 (+/+) and (-/-) lines using CRISPR/Cas9 as previously
537 described for *Ae. aegypti* (Kistler et al., 2015). The single-guide RNAs (sgRNAs) were
538 designed using CRISPOR (<http://crispor.tefor.net/>) by searching for 20-bp sgRNAs
539 with the NGG protospacer-adjacent-motif (PAM). In order to reduce chances of off-
540 target mutations, only sgRNAs with off-target sites which contained three or more
541 mismatches were selected. Two sgRNAs with cut-sites proximal to the boundaries of
542 the CFAV-EVE1 were chosen in order to delete the full CFAV-EVE1 sequence. A third
543 sgRNA in the middle of the EVE sequence was added to facilitate deletion of the CFAV-
544 EVE1 sequence. sgRNA sequences with their most probable off-target sites are
545 represented in Table S3. SgRNAs were produced as previously described (Kistler et
546 al., 2015). Double-stranded DNA templates for each sgRNA were produced by
547 template-free PCR with two partially overlapping oligos (PAGE-purified, Sigma-
548 Aldrich). Where necessary, one or two guanines were added to the 5' end of the guide
549 sequence within the primer to ensure the format "5'-GG(N18-20)-3'" in order to facilitate
550 *in vitro* transcription with MEGAscript T7 *in vitro* transcription kit (Ambion). Transcribed
551 sgRNAs were purified with MEGAclean kit (Invitrogen). Quality of sgRNAs were
552 assessed with Bioanalyzer, Agilent 2100 Small RNA kit (Agilent).

553 *Repair template design*

554 We designed a 110-nt repair template with homology arms (HA) to the upstream and
555 downstream flanking regions of the CFAV-EVE1 and extending to the sgRNA cut-sites
556 (3 bp upstream of the PAM). The annotated sequence of the repair template is provided
557 in Table S3. Due to the 5' sgRNA having a cut-site inside the CFAV-EVE1 sequence,
558 mismatches were artificially incorporated into to the 5' HA of the repair template to

559 ensure disruption of the CFAV-EVE1 sequence while maintaining enough homology
560 to facilitate homologous recombination and deletion of CFAV-EVE1. An sgRNA
561 sequence (with PAM) exogenous to the *Ae. aegypti* genome was also included in the
562 repair template in an attempt to incorporate this guide sequence for further
563 CRISPR/Cas9-mediated mutagenesis of this site. However, this and the modified
564 CFAV-EVE1 sequences ultimately failed to get incorporated in CFAV-EVE1 (-/-) line
565 genome. This could be explained by the presence of the 5'-TAAAAGTGGCGACGAG-
566 3' sequence contained in each flanking region of the CFAV-EVE1 that might have
567 mediated the homology-dependent double-strand break repair independently of the
568 repair template or that one homology arm acted as a truncated repair template.

569 *Egg microinjection*

570 The final microinjection mix contained 322 ng/μL spCas9 protein (New England
571 Biolabs) with 40 ng/μL of each sgRNA and 127 ng/μL of the ssDNA repair template.
572 The microinjection of *Ae. aegypti* embryos was performed according to standard
573 protocols (Jasinskiene et al., 2007). *Ae. aegypti* females were engorged with
574 commercial rabbit blood (BCL) via an artificial membrane feeding system (Hemotek).
575 At least 3 days post blood meal, females were transferred into egg-laying vials and
576 oviposition was induced by placing mosquitoes into dark conditions. Embryos were
577 injected 30-60 min post oviposition. Embryos were hatched by being placed in water
578 at least 3 days post injection and reared to adult stage as described above under
579 mosquito maintenance. The generation 0 (G0) virgin adult mosquitoes were genotyped
580 using a single leg DNA by PCR with EVE-GTlong-external primers (Table S1). The
581 deletion in the CFAV-EVE1 heterozygous PCR products was confirmed by Sanger
582 sequencing.

583 *Generation of the CFAV-EVE1 (+/+) and (-/-) lines*

584 A single male mosquito (G0) with a verified CFAV-EVE1 heterozygous genotype was
585 mated with 20 wild-type females. The progeny (G1) were genotyped and 7
586 heterozygous males were mated with 35 wild-type females. G2 progeny were
587 genotyped and 14 heterozygous males were mated with 22 heterozygous females. G3
588 progeny were genotyped and pure CFAV-EVE1 (+/+) and CFAV-EVE1 (-/-) lines were
589 created by pooling homozygous positive (11 males and 31 females) and negative (11
590 males and 18 females) mosquitoes, respectively. The progeny of these crosses (F1)
591 were verified by the PCR with CFAV-EVE1 external primers in 3 pools of 20
592 mosquitoes from each line. The lines were reared according to the standard rearing
593 procedures described above. Further line genotype verification was performed at F3,
594 F4, and F5. The F4 generation of mosquitoes was used for sRNA sequencing, which
595 confirmed the almost complete absence of sRNAs complementary to CFAV in the
596 CFAV-EVE1 (-/-) line, hence, the purity of the CFAV-EVE1 deletion and the absence
597 of any other CFAV-related EVE that could have produced sRNAs.

598 **CFAV experimental infections *in vivo***

599 *CFAV isolate and injection conditions*

600 A wild-type CFAV strain (CFAV-KPP; ENA accession number LR596014) previously
601 isolated from the *Ae. aegypti* outbred laboratory colony (Baidaliuk et al., 2019) was
602 used for experimental infections of the CFAV-free *Ae. aegypti* isofemale line and the
603 genetically modified lines. The first intrathoracic injection of the *Ae. aegypti* isofemale
604 line harboring the CFAV-EVE1 was done with the third passage post isolation of the
605 CFAV-KPP strain. The female mosquitoes were injected with 786 50% tissue-culture
606 infectious dose (TCID₅₀) units of virus per body using Nanoject II Auto-Nanoliter
607 Injector (Drummond), then sacrificed on day 7 post injection and pooled RNA from 10
608 whole bodies was used for the first sRNA library preparation and sequencing. Mock

609 injections were performed with naïve C6/36 cell-culture supernatant. The CFAV-KPP
610 strain was also used for experimental infections of CFAV-EVE1 (+/+) and (-/-) lines
611 (referred to as experiments 1-6), although it was produced from the viral genomic RNA
612 instead of mosquito homogenates (Baidaliuk et al., 2019). Female mosquitoes were
613 intrathoracically injected with 50 TCID₅₀ units of CFAV-KPP per body in experiments
614 1-6 using Nanoject III Programmable Nanoliter Injector (Drummond). In experiment 5,
615 mock injection was done with the naïve C6/36 cell-culture supernatant. RNA from the
616 pools of heads and ovaries of injected females dissected on day 4 (experiments 1-5)
617 or on day 7 (experiments 4-6) was used for the RT-qPCR with CFAV-specific primers
618 and additionally for sRNA sequencing (experiment 5, day 7). In experiment 1, RNA
619 was extracted from 5 pools of 4 tissues (pairs of ovaries or heads in all 6 experiments)
620 per condition (mosquito line). In experiment 2, RNA was extracted from 6 pools of 5
621 tissues per condition (mosquito line). In experiment 3, RNA was extracted from 8 pools
622 of 4 tissues per condition (mosquito line). In experiment 4, RNA was extracted from 6-
623 8 pools of 4 tissues per condition (mosquito line and day post injection). In experiment
624 5, RNA was extracted from 5 pools of 9 tissues per condition (mosquito line and day
625 post injection). Finally, in experiment 6, RNA was extracted from 5 pools of 5 tissues
626 per condition (mosquito line). Mosquitoes were from generation F3 in experiments 1-
627 4, generation F4 in experiment 5, and generation F6 in experiment 6.

628 *CFAV RNA quantification*

629 Total RNA was extracted and purified from mosquito tissues using TRIzol Reagent
630 (Invitrogen) following manufacturer's instructions with RNA elution in 30 µL of PCR-
631 grade water. cDNA synthesis was performed using M-MLV reverse transcriptase
632 (Invitrogen) by mixing 10 µL of eluted RNA with 100 ng of random primers (Roche), 10
633 nmol of each dNTP, 2 µL of DTT, 4 µL of 5X First-Strand Buffer, 0.5 µL of PCR-grade

634 water, 20 units of RNaseOUT recombinant ribonuclease inhibitor (Invitrogen), and 200
635 units of M-MLV reverse transcriptase in a final reaction volume of 20 μ L. Reactions
636 were incubated for 10 min at 25°C, 50 min at 37°C, 15 min at 70°C, and held at 4°C
637 until further use or stored at -20°C. cDNA was diluted 1:5 before quantitative analysis
638 by qPCR was done using GoTaq qPCR Master Mix (Promega) following
639 manufacturer's recommendations. Primer sequences are provided in Table S2. CFAV
640 qPCR values were normalized by the housekeeping gene *rp49* qPCR values and the
641 normalized CFAV RNA levels were log₁₀-transformed prior to their statistical analysis.
642 A pool of mosquito tissues was considered a biological unit of replication. Type III
643 multivariate analysis of variance (MANOVA) was performed separately for each time
644 point (day 4 and day 7 post injection) and each tissue type (heads and ovaries). The
645 linear model included experiment, mosquito line, and their interaction as covariates.
646 The interaction term was removed from the model when its effect was statistically non-
647 significant ($p > 0.05$), and type II MANOVA was performed instead. Statistical analyses
648 were performed in the statistical environment R, version 3.5.2 ([http://www.r-](http://www.r-project.org/)
649 [project.org/](http://www.r-project.org/)).

650

651 **Small-RNA sequencing**

652 *sRNA library preparation and sequencing*

653 Total RNA from pools of 5 to 10 mosquitoes was subjected to acrylamide gel (15%
654 acrylamide/bisacrylamie, 37.5:1, and 7M urea) electrophoresis to purify sRNAs of 19-
655 33 nt in length. Purified sRNAs were used for library preparation with NEBNext
656 Multiplex Small RNA Library Prep (Illumina) with 3' adaptor, Universal miRNA Cloning
657 Linker – S1315S (Biolabs) and in-house designed indexed primers. Libraries were

658 diluted to 4 nM and sequenced on a NextSeq 500 sequencer (Illumina) with a NextSeq
659 500 High-Output Kit v2 (Illumina) (52 cycles).

660 *Analyses of small-RNA sequencing data*

661 The quality of the fastq files was assessed with FastQC software
662 (www.bioinformatics.babraham.ac.uk/projects/fastqc/). Low-quality bases and
663 adaptors were trimmed from each read using Cutadapt. Only reads with an acceptable
664 quality (Phred score >20) and the adaptor sequence at the 5' end were retained. A
665 second set of graphics was generated by the FastQC software using the fastq files
666 trimmed using Cutadapt. Reads were mapped to target sequences using Bowtie1 (one
667 mismatch allowed between the read and its target for initial mapping or no mismatch
668 allowed for target-specific mapping) or the Bowtie2 tool with default options for the
669 sRNA or DNA library, respectively. The Bowtie1 tool (sRNA library) and the Bowtie2
670 tool (DNA library) generate results in sequence alignment/map (SAM) format. All SAM
671 files were analyzed by the SAMtools package to produce bam indexed files.
672 Homemade R scripts with Rsamtools and Shortreads in Bioconductor software were
673 used for analysis of the bam files. For the analysis of sequence logos and sRNA
674 overlaps, sRNA reads aligned to the CFAV-EVE1 sequence or to the CFAV genomic
675 RNA were processed in Galaxy (Afgan et al., 2018). To generate sequence logos,
676 reads of 26-30 nt in length were filtered and separated according to their genomic
677 orientation. The selected reads were converted into FastA format, trimmed at the 3'
678 end to 20 nt and converted to RNA letters using the corresponding FastA/FastQ tools.
679 The processed reads were used as input for the Weblogo tool available in the Galaxy
680 toolshed (Crooks et al., 2004). For the analysis of ping-pong signatures, aligned reads
681 were loaded into the Mississippi instance of Galaxy (<https://mississippi.snv.jussieu.fr/>).
682 SAM files containing the reads of 26-30 nt in length were used as input for the Small

683 RNA signatures tool. The Z-scores of the calculated overlap probabilities were plotted
684 with Graphpad Prism. All sRNA sequencing library sizes with the number of CFAV-
685 mapped reads are reported in Table S5. All data are available in the Sequence Read
686 Archive repository under project PRJNA588447.

687 **Table S1. Primers used in this study.**

688

689 **Table S2. CFAV-EVE1 and CFAV-EVE2 sequence annotation based on similarity**

690 **to the CFAV-KPP genome.** The CFAV-EVE1 sequence was reconstructed from the
691 WGS data of the CFAV-free isofemale line from Thailand generated in this study.

692 CFAV-EVE1 sequences extracted from the AaegL3 assembly and reconstructed from

693 a published WGS dataset (SRA sample SRR5562867) are also provided. The CFAV-

694 EVE2 sequence was reconstructed from published RNA-seq data of the lower

695 reproductive tract of *Ae. aegypti* derived from Thailand (SRA samples

696 SAMN04480331, SAMN04480332, and SAMN04480333).

697

698 **Table S3. CRISPR/Cas9 design for CFAV-EVE1 knockout.**

699

700 **Table S4. Analysis of variance of CFAV RNA levels in tissues of CFAV-infected**

701 **CFAV-EVE1 (+/+) and (-/-) *Aedes aegypti* mosquito lines.**

702 Multivariate analysis of variance (MANOVA) of relative CFAV RNA levels (normalized

703 to the *rp49* housekeeping gene) was performed for each time point and tissue

704 separately. The model included the effects of the experiment, the mosquito line and

705 their interaction (when significant). The stars indicate the statistical significance of the

706 effect (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). *Df* = degrees of freedom; *F* = *F* statistic; *p*

707 = *p* value.

708

709 **Table S5. sRNA library information.**

710

711 References

- 712 Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Cech, M., Chilton, J.,
713 Clements, D., Coraor, N., Gruning, B.A., *et al.* (2018). The Galaxy platform for
714 accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic*
715 *Acids Res* 46, W537-W544.
- 716 Akbari, O.S., Antoshechkin, I., Amrhein, H., Williams, B., Diloreto, R., Sandler, J., and
717 Hay, B.A. (2013). The developmental transcriptome of the mosquito *Aedes aegypti*, an
718 invasive species and major arbovirus vector. *G3 (Bethesda)* 3, 1493-1509.
- 719 Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local
720 alignment search tool. *J Mol Biol* 215, 403-410.
- 721 Anderson, M.M., Lauring, A.S., Burns, C.C., and Overbaugh, J. (2000). Identification
722 of a cellular cofactor required for infection by feline leukemia virus. *Science* 287, 1828-
723 1830.
- 724 Anderson, R.M., and May, R.M. (1982). Coevolution of hosts and parasites.
725 *Parasitology* 85 (Pt 2), 411-426.
- 726 Baidaliuk, A., Lequime, S., Moltini-Conclois, I., Dabo, S., Dickson, L.B., Prot, M.,
727 Duong, V., Dussart, P., Boyer, S., Shi, C., *et al.* (in press). Novel genome sequences
728 of cell-fusing agent virus allow comparison of virus phylogeny with the genetic structure
729 of *Aedes aegypti* populations. *Virus Evol.*
- 730 Baidaliuk, A., Miot, E.F., Lequime, S., Moltini-Conclois, I., Delaigue, F., Dabo, S.,
731 Dickson, L.B., Aubry, F., Merkling, S.H., Cao-Lormeau, V.M., *et al.* (2019). Cell-Fusing
732 Agent Virus Reduces Arbovirus Dissemination in *Aedes aegypti* Mosquitoes In Vivo. *J*
733 *Virol* 93.
- 734 Ballenghien, M., Faivre, N., and Galtier, N. (2017). Patterns of cross-contamination in
735 a multispecies population genomic project: detection, quantification, impact, and
736 solutions. *BMC Biol* 15, 25.
- 737 Belyi, V.A., Levine, A.J., and Skalka, A.M. (2010). Unexpected inheritance: multiple
738 integrations of ancient bornavirus and ebolavirus/marburgvirus sequences in
739 vertebrate genomes. *PLoS Pathog* 6, e1001030.
- 740 Bender, W., Spierer, P., and Hogness, D.S. (1983). Chromosomal walking and jumping
741 to isolate DNA from the *Ace* and *rosy* loci and the *bithorax* complex in *Drosophila*
742 *melanogaster*. *J Mol Biol* 168, 17-33.
- 743 Best, S., Le Tissier, P., Towers, G., and Stoye, J.P. (1996). Positional cloning of the
744 mouse retrovirus restriction gene *Fv1*. *Nature* 382, 826-829.
- 745 Blair, C.D. (2019). Deducing the Role of Virus Genome-Derived PIWI-Associated
746 RNAs in the Mosquito-Arbovirus Arms Race. *Front Genet* 10, 1114.
- 747 Blair, C.D., Olson, K.E., and Bonizzoni, M. (2020). The Widespread Occurrence and
748 Potential Biological Roles of Endogenous Viral Elements in Insect Genomes. *Curr*
749 *Issues Mol Biol* 34, 13-30.
- 750 Boisvert, S., Laviolette, F., and Corbeil, J. (2010). Ray: simultaneous assembly of
751 reads from a mix of high-throughput sequencing technologies. *J Comput Biol* 17, 1519-
752 1533.

- 753 Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for
754 Illumina sequence data. *Bioinformatics* 30, 2114-2120.
- 755 Brennecke, J., Aravin, A.A., Stark, A., Dus, M., Kellis, M., Sachidanandam, R., and
756 Hannon, G.J. (2007). Discrete small RNA-generating loci as master regulators of
757 transposon activity in *Drosophila*. *Cell* 128, 1089-1103.
- 758 Chabas, H., Nicot, A., Meaden, S., Westra, E.R., Tremblay, D.M., Pradier, L., Lion, S.,
759 Moineau, S., and Gandon, S. (2019). Variability in the durability of CRISPR-Cas
760 immunity. *Philos Trans R Soc Lond B Biol Sci* 374, 20180097.
- 761 Cosby, R.L., Chang, N.C., and Feschotte, C. (2019). Host-transposon interactions:
762 conflict, cooperation, and cooption. *Genes Dev* 33, 1098-1116.
- 763 Crooks, G.E., Hon, G., Chandonia, J.M., and Brenner, S.E. (2004). WebLogo: a
764 sequence logo generator. *Genome Res* 14, 1188-1190.
- 765 Czech, B., and Hannon, G.J. (2016). One Loop to Rule Them All: The Ping-Pong Cycle
766 and piRNA-Guided Silencing. *Trends Biochem Sci* 41, 324-337.
- 767 Czech, B., Munafo, M., Ciabrelli, F., Eastwood, E.L., Fabry, M.H., Kneuss, E., and
768 Hannon, G.J. (2018). piRNA-Guided Genome Defense: From Biogenesis to Silencing.
769 *Annu Rev Genet* 52, 131-157.
- 770 Ewald, P.W. (1983). Host-Parasite Relations, Vectors, and the Evolution of Disease
771 Severity. *Annu Rev Ecol Syst* 14, 465-485.
- 772 Ewald, P.W. (1987). Transmission modes and evolution of the parasitism-mutualism
773 continuum. *Ann N Y Acad Sci* 503, 295-306.
- 774 Fansiri, T., Fontaine, A., Diancourt, L., Caro, V., Thaisomboonsuk, B., Richardson,
775 J.H., Jarman, R.G., Ponlawat, A., and Lambrechts, L. (2013). Genetic mapping of
776 specific interactions between *Aedes aegypti* mosquitoes and dengue viruses. *Plos*
777 *Genet* 9, e1003621.
- 778 Firth, A.E., Blitvich, B.J., Wills, N.M., Miller, C.L., and Atkins, J.F. (2010). Evidence for
779 ribosomal frameshifting and a novel overlapping gene in the genomes of insect-specific
780 flaviviruses. *Virology* 399, 153-166.
- 781 Flynn, P.J., and Moreau, C.S. (2019). Assessing the Diversity of Endogenous Viruses
782 Throughout Ant Genomes. *Front Microbiol* 10, 1139.
- 783 Frank, J.A., and Feschotte, C. (2017). Co-option of endogenous viral sequences for
784 host cell function. *Curr Opin Virol* 25, 81-89.
- 785 Fujino, K., Horie, M., Honda, T., Merriman, D.K., and Tomonaga, K. (2014). Inhibition
786 of Borna disease virus replication by an endogenous bornavirus-like element in the
787 ground squirrel genome. *Proc Natl Acad Sci U S A* 111, 13175-13180.
- 788 Gilbert, C., and Feschotte, C. (2010). Genomic fossils calibrate the long-term evolution
789 of hepadnaviruses. *PLoS Biol* 8.
- 790 Goertz, G.P., Miesen, P., Overheul, G.J., van Rij, R.P., van Oers, M.M., and Pijlman,
791 G.P. (2019). Mosquito Small RNA Responses to West Nile and Insect-Specific Virus
792 Infections in *Aedes* and *Culex* Mosquito Cells. *Viruses* 11.
- 793 Goic, B., Stapleford, K.A., Frangeul, L., Doucet, A.J., Gausson, V., Blanc, H.,
794 Schemmel-Jofre, N., Cristofari, G., Lambrechts, L., Vignuzzi, M., *et al.* (2016). Virus-

- 795 derived DNA drives mosquito vector tolerance to arboviral infection. *Nat Commun* 7,
796 12410.
- 797 Gunawardane, L.S., Saito, K., Nishida, K.M., Miyoshi, K., Kawamura, Y., Nagami, T.,
798 Siomi, H., and Siomi, M.C. (2007). A slicer-mediated mechanism for repeat-associated
799 siRNA 5' end formation in *Drosophila*. *Science* 315, 1587-1590.
- 800 Halbach, R., Miesen, P., Joosten, J., Taşköprü, E., Pennings, B., Vogels, C.B.F.,
801 Merkling, S.H., Koenraad, C.J., Lambrechts, L., and van Rij, R.P. (2020). An ancient
802 satellite repeat controls gene expression and embryonic development in *Aedes aegypti*
803 through a highly conserved piRNA. *bioRxiv*, 2020.2001.2015.907428.
- 804 Holmes, E.C. (2011). The evolution of endogenous viral elements. *Cell Host Microbe*
805 10, 368-377.
- 806 Horie, M., Honda, T., Suzuki, Y., Kobayashi, Y., Daito, T., Oshida, T., Ikuta, K., Jern,
807 P., Gojobori, T., Coffin, J.M., *et al.* (2010). Endogenous non-retroviral RNA virus
808 elements in mammalian genomes. *Nature* 463, 84-87.
- 809 Huang, X.A., Yin, H., Sweeney, S., Raha, D., Snyder, M., and Lin, H. (2013). A major
810 epigenetic programming mechanism guided by piRNAs. *Dev Cell* 24, 502-516.
- 811 Jasinskiene, N., Juhn, J., and James, A.A. (2007). Microinjection of *A. aegypti* embryos
812 to obtain transgenic mosquitoes. *J Vis Exp*, 219.
- 813 Katzourakis, A., Aiewsakun, P., Jia, H., Wolfe, N.D., LeBreton, M., Yoder, A.D., and
814 Switzer, W.M. (2014). Discovery of prosimian and afrotherian foamy viruses and
815 potential cross species transmissions amidst stable and ancient mammalian co-
816 evolution. *Retrovirology* 11, 61.
- 817 Kistler, K.E., Vosshall, L.B., and Matthews, B.J. (2015). Genome engineering with
818 CRISPR-Cas9 in the mosquito *Aedes aegypti*. *Cell Rep* 11, 51-60.
- 819 Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2.
820 *Nat Methods* 9, 357-359.
- 821 Leinonen, R., Sugawara, H., Shumway, M., and International Nucleotide Sequence
822 Database, C. (2011). The sequence read archive. *Nucleic Acids Res* 39, D19-21.
- 823 Lequime, S., Fontaine, A., Ar Gouilh, M., Moltini-Conclois, I., and Lambrechts, L.
824 (2016). Genetic Drift, Purifying Selection and Vector Genotype Shape Dengue Virus
825 Intra-host Genetic Diversity in Mosquitoes. *Plos Genet* 12, e1006111.
- 826 Lequime, S., Richard, V., Cao-Lormeau, V.M., and Lambrechts, L. (2017). Full-
827 genome dengue virus sequencing in mosquito saliva shows lack of convergent positive
828 selection during transmission by *Aedes aegypti*. *Virus Evol* 3.
- 829 Lewis, S.H., Quarles, K.A., Yang, Y., Tanguy, M., Frezal, L., Smith, S.A., Sharma, P.P.,
830 Cordaux, R., Gilbert, C., Giraud, I., *et al.* (2018). Pan-arthropod analysis reveals
831 somatic piRNAs as an ancestral defence against transposable elements. *Nat Ecol Evol*
832 2, 174-181.
- 833 Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput
834 sequencing reads. *2011* 17, 3.
- 835 Miesen, P., Joosten, J., and van Rij, R.P. (2016). PIWIs Go Viral: Arbovirus-Derived
836 piRNAs in Vector Mosquitoes. *PLoS Pathog* 12, e1006017.

- 837 Morazzani, E.M., Wiley, M.R., Murreddu, M.G., Adelman, Z.N., and Myles, K.M.
838 (2012). Production of virus-derived ping-pong-dependent piRNA-like small RNAs in the
839 mosquito soma. *PLoS Pathog* 8, e1002470.
- 840 Nurk, S., Meleshko, D., Korobeynikov, A., and Pevzner, P.A. (2017). metaSPAdes: a
841 new versatile metagenomic assembler. *Genome Res* 27, 824-834.
- 842 Ophinni, Y., Palatini, U., Hayashi, Y., and Parrish, N.F. (2019). piRNA-Guided
843 CRISPR-like Immunity in Eukaryotes. *Trends Immunol* 40, 998-1010.
- 844 Ozata, D.M., Gainetdinov, I., Zoch, A., O'Carroll, D., and Zamore, P.D. (2019). PIWI-
845 interacting RNAs: small RNAs with big functions. *Nat Rev Genet* 20, 89-108.
- 846 Palatini, U., Miesen, P., Carballar-Lejarazu, R., Ometto, L., Rizzo, E., Tu, Z., van Rij,
847 R.P., and Bonizzoni, M. (2017). Comparative genomics shows that viral integrations
848 are abundant and express piRNAs in the arboviral vectors *Aedes aegypti* and *Aedes*
849 *albopictus*. *BMC Genomics* 18, 512.
- 850 Parrish, N.F., Fujino, K., Shiromoto, Y., Iwasaki, Y.W., Ha, H., Xing, J., Makino, A.,
851 Kuramochi-Miyagawa, S., Nakano, T., Siomi, H., *et al.* (2015). piRNAs derived from
852 ancient viral processed pseudogenes as transgenerational sequence-specific immune
853 memory in mammals. *RNA* 21, 1691-1703.
- 854 Parry, R., and Asgari, S. (2019). Discovery of novel crustacean and cephalopod
855 flaviviruses: insights into evolution and circulation of flaviviruses between marine
856 invertebrate and vertebrate hosts. *Journal of Virology*, JVI.00432-00419.
- 857 Petit, M., Mongelli, V., Frangeul, L., Blanc, H., Jiggins, F., and Saleh, M.C. (2016).
858 piRNA pathway is not required for antiviral defense in *Drosophila melanogaster*. *Proc*
859 *Natl Acad Sci U S A* 113, E4218-4227.
- 860 Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for comparing
861 genomic features. *Bioinformatics* 26, 841-842.
- 862 Rückert, C., Prasad, A.N., Garcia-Luna, S.M., Robison, A., Grubaugh, N.D., Weger-
863 Lucarelli, J., and Ebel, G.D. (2019). Small RNA responses of *Culex* mosquitoes and
864 cell lines during acute and persistent virus infection. *Insect Biochem Mol Biol* 109, 13-
865 23.
- 866 Russo, A.G., Kelly, A.G., Enosi Tuipulotu, D., Tanaka, M.M., and White, P.A. (2019).
867 Novel insights into endogenous RNA viral elements in. *Virus Evol* 5, vez010.
- 868 Sun, Y.H., Xie, L.H., Zhuo, X., Chen, Q., Ghoneim, D., Zhang, B., Jagne, J., Yang, C.,
869 and Li, X.Z. (2017). Domestic chickens activate a piRNA defense against avian
870 leukosis virus. *Elife* 6.
- 871 Suzuki, Y., Frangeul, L., Dickson, L.B., Blanc, H., Verdier, Y., Vinh, J., Lambrechts, L.,
872 and Saleh, M.C. (2017). Uncovering the Repertoire of Endogenous Flaviviral Elements
873 in *Aedes* Mosquito Genomes. *J Virol* 91.
- 874 Tassetto, M., Kunitomi, M., Whitfield, Z.J., Dolan, P.T., Sanchez-Vargas, I., Garcia-
875 Knight, M., Ribiero, I., Chen, T., Olson, K.E., and Andino, R. (2019). Control of RNA
876 viruses in mosquito cells through the acquisition of vDNA and endogenous viral
877 elements. *Elife* 8.
- 878 Ter Horst, A.M., Nigg, J.C., Dekker, F.M., and Falk, B.W. (2019). Endogenous Viral
879 Elements Are Widespread in Arthropod Genomes and Commonly Give Rise to PIWI-
880 Interacting RNAs. *J Virol* 93.

- 881 Vodovar, N., Bronkhorst, A.W., van Cleef, K.W., Miesen, P., Blanc, H., van Rij, R.P.,
882 and Saleh, M.C. (2012). Arbovirus-derived piRNAs exhibit a ping-pong signature in
883 mosquito cells. *Plos One* 7, e30861.
- 884 Waldron, F.M., Stone, G.N., and Obbard, D.J. (2018). Metagenomic sequencing
885 suggests a diversity of RNA interference-like responses to viruses across multicellular
886 eukaryotes. *Plos Genet* 14, e1007533.
- 887 Whitfield, Z.J., Dolan, P.T., Kunitomi, M., Tassetto, M., Seetin, M.G., Oh, S., Heiner,
888 C., Paxinos, E., and Andino, R. (2017). The Diversity, Structure, and Function of
889 Heritable Adaptive Immunity Sequences in the *Aedes aegypti* Genome. *Curr Biol* 27,
890 3511-3519 e3517.
- 891 Wilm, A., Aw, P.P., Bertrand, D., Yeo, G.H., Ong, S.H., Wong, C.H., Khor, C.C., Petric,
892 R., Hibberd, M.L., and Nagarajan, N. (2012). LoFreq: a sequence-quality aware, ultra-
893 sensitive variant caller for uncovering cell-population heterogeneity from high-
894 throughput sequencing datasets. *Nucleic Acids Res* 40, 11189-11201.
- 895 Zakrzewski, M., Rasic, G., Darbro, J., Krause, L., Poo, Y.S., Filipovic, I., Parry, R.,
896 Asgari, S., Devine, G., and Suhrbier, A. (2018). Mapping the virome in wild-caught
897 *Aedes aegypti* from Cairns and Bangkok. *Sci Rep-Uk* 8.
- 898




Figure 1. CFAV-derived endogenous viral elements interact with natural CFAV infection through the piRNA pathway.

A. The schematic represents two potential CFAV EVE structures detected in publicly available *Ae. aegypti* sequences (See also Figure S1 and Table S2). **B.** The presence of putative CFAV-

EVE1 and CFAV-EVE2 in eight mosquitoes from the same outbred colony was verified by PCR with primers specific to CFAV-EVE1 (left), CFAV-EVE2 (middle), and *rps7* gene control (right). **C-D.** Size distribution of sRNAs mapping to the CFAV genome from naturally CFAV-uninfected (**C**) and CFAV-infected (**D**) mosquitoes from the outbred colony. **E-F.** Analysis of CFAV-derived piRNAs from naturally CFAV-uninfected (**E**) and CFAV-infected (**F**) mosquitoes from the outbred colony. Mapping of 26-30 nt sRNAs (top), sequence logos of 26-30 nt sRNAs (bottom-left), and overlap probability of 26-30 nt sRNAs (bottom-right). Sequence logos and overlap probability for CFAV-EVE1 were restricted to the NS2 region. In panels **C-F**, positive- and negative-sense reads with respect to the reference CFAV genome are shown in yellow and blue, respectively. Uncovered nucleotides are represented by gray lines.




Figure 2. CFV-EVE1 interacts with experimental CFV infection through the piRNA pathway.

A. Schematic of the CFV-EVE1 structure in the CFV-free isofemale line represented as the alignment of the EVE locus in the *Ae. aegypti* genome assembly AegL3 (top) to the genome of the CFV-KPP strain (bottom). CFV-EVE1 comprises four different regions of the CFV genome. Yellow and blue colors indicate forward and reverse strands, respectively, according to the transcription direction in the supercontig. **B.** Production of piRNAs from CFV-EVE1 in

the CFAV-free isofemale line, represented as the size distribution (left) and alignment to the CFAV-EVE-1 locus (right). Blue color corresponds to negative-sense reads with respect to the mapping reference. **C-D**. Size distribution of sRNAs mapping to the CFAV genome from experimentally CFAV-uninfected (**C**) and CFAV-infected (**D**) mosquitoes from the isofemale line. **E-F**. Analysis of CFAV-derived piRNAs from experimentally CFAV-uninfected (**E**) and CFAV-infected (**F**) mosquitoes from the isofemale line. Mapping of 26-30 nt sRNAs (top), sequence logos of 26-30 nt sRNAs (bottom-left), and overlap probability of 26-30 nt sRNAs (bottom-right). Sequence logos and overlap probability were restricted to the NS2 region. In panels **C-F**, positive- and negative-sense reads with respect to the reference CFAV genome are shown in yellow and blue, respectively. Uncovered nucleotides are represented by gray lines. See also Figure S2 and Figure S3.




Figure 3. CRISPR/Cas9-mediated genome editing of CFAV-EVE1 in *Aedes aegypti*.

A. Deletion of the CFAV-EVE1 from the *Ae. aegypti* genome of the CFAV-free isofemale line using CRISPR/Cas9. The upper bar represents the CFAV-EVE1 with the flanking regions and the three sgRNA target sites are shown with scissors. The lower bar represents the merged flanking regions without the CFAV-EVE1, where the short repeat sequences in the flanking regions (yellow segments on both bars) are merged into one. **B.** Generation of the CFAV-EVE1 (+/+) and (-/-) *Ae. aegypti* lines after CRISPR/Cas9-mediated genome editing. A single G0 male mosquito heterozygous for the CFAV-EVE1 deletion (+/-) was outcrossed with wild-type females harboring the CFAV-EVE1. The resulting heterozygous male G1 progeny was outcrossed with wild-type females harboring the CFAV-EVE1. The G2 heterozygotes of both sexes were intercrossed to produce a mixed G3 progeny that was sorted into pure homozygous CFAV-EVE1 (+/+) and (-/-) lines. The letter G denotes the generation of mosquitoes originating from the CFAV-EVE1 heterozygous male and wild-type females. The

letter F denotes the generation of the CFAV-EVE1 homozygous lines. The agarose gel picture represents a fraction of samples genotyped at G3, where the pure homozygous individuals were selected by PCR genotyping of a single leg. See also Table S3.




Figure 4. Ablation of CFAV-EVE1 prevents CFAV-derived piRNA amplification.

Size distribution of sRNAs mapping to the CFAV genome in ovaries (A-B) and heads (E-F) from experimentally infected CFAV-EVE1 (+/+) (A,E) and CFAV-EVE1 (-/-) (B,F) mosquitoes 7 days post injection. Analysis of CFAV-derived piRNAs in ovaries (C-D) and heads (G-H) from

experimentally infected CFAV-EVE1 (+/+) (**C,G**) and CFAV-EVE1 (-/-) (**D,H**) mosquitoes 7 days post injection. Mapping of 26-30 nt sRNAs (top), sequence logos of 26-30 nt sRNAs (bottom-left), and overlap probability of 26-30 nt sRNAs (bottom-right). Sequence logos and overlap probability were restricted to the NS2 region. In all panels, positive- and negative-sense reads with respect to the reference CFAV genome are shown in yellow and blue, respectively. Uncovered nucleotides are represented by gray lines. See also Figure S4 and Figure S5.




Figure 5. CFAV-EVE1 ablation results in increased CFAV RNA levels upon viral infection.

A-B. Relative CFAV RNA levels (normalized by the *rp49* housekeeping gene) in heads and ovaries of the CFAV-EVE1 (+/+) (black boxplot) and CFAV-EVE1 (-/-) (white boxplot) *Ae. aegypti* lines on day 4 (**A**) and day 7 (**B**) post CFAV inoculation. Data are shown for six separate experiments represented by color- and symbol-coded data points. Relative viral RNA loads are represented by box plots in which the box denotes the median and interquartile range (IQR) and the whiskers extend to the highest and lowest outliers within 1.5 times the IQR from the upper and lower quartiles, respectively. Multivariate analysis of variance (MANOVA) was performed for each time point and tissue separately, accounting for the experiment, mosquito line and interaction effects. Stars indicate statistical significance of the mosquito line main effect accounting for the experiment effect (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns = not significant). The full MANOVA results are provided in Table S4.




Figure 6. Model for the antiviral role of non-retroviral EVEs in mosquitoes.

Both a naturally occurring EVE (left panel) and exogenous viral infection (middle panel) produce primary piRNAs, in antisense and sense orientation, respectively. Only when EVE and virus are present in the same mosquito, do piRNAs acquire antiviral activity (right panel) through EVE-derived piRNAs targeting the viral genome. Under this model, integration of non-retroviral sequences into the host genome, their transcription into piRNA precursors, and their processing into antiviral piRNAs are a mechanism by which EVEs confer heritable, sequence-specific host immunity.